Physician profile
Larry Tetsoti
NPI 1437104361
$2,595.81
in general payments reported to CMS, 2019-2025
16 companies · $314 in 2025
The $314 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $118 · 2021: $262 · 2022: $476 · 2023: $459 · 2024: $831 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,603.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $1,112.86 | 2023-2025 | Gemtesa, Orgovyx |
| Urovant Sciences INC | $364.08 | 2021-2022 | |
| Bioprotect Medical, INC. | $237.86 | 2024 | Bioprotect Balloon Implant System |
| Teleflex LLC | $182.13 | 2024 | |
| Myovant Sciences INC. | $175.62 | 2021-2022 | |
| Pfizer INC. | $113.03 | 2019-2021 | |
| Verity Pharmaceuticals INC. | $81.18 | 2021-2024 | Trelstar |
| Astellas Pharma US INC | $77.71 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $50.99 | 2021-2023 | Prolaris |
| Merck Sharp & Dohme LLC | $35.68 | 2021-2022 | |
| Boston Scientific Corporation | $33.10 | 2023 | Rezum Generator |
| Amgen INC. | $30.68 | 2021 | |
| Neotract INC. | $29.52 | 2020 | |
| Janssen Biotech, INC. | $28.74 | 2020 | |
| Novartis Pharmaceuticals Corporation | $21.50 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $21.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Tetsoti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.